NYN. Y. Yermek

N. Y. Yermek

*This is an algorithmically generated author record based on publicly available information.

N. Y. Yermek has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TRENDS IN INCIDENCE, STAGE DISTRIBUTION, AND MORTALITY OF PROSTATE CANCER IN THE AKMOLA REGION, 2005–2024

    by Z.A. Bilyalova, N.Y. Yermek, Zh.B. Telmanova, I.YU. Shishkin, G.S. Igissinova, S.S. Dyakov, D.K. Turebayev, A.M. Kazhitaev, G.Z. Khairli, N.S. Igissin

    Background. Regional analyses integrating prostate cancer incidence, stage at diagnosis, and mortality can identify epidemiological patterns that may be obscured by national estimates. Such evidence remains limited for Akmola Region. Objective. To characterize the age profile of prostate cancer and determine how incidence, diagnostic-stage composition, mortality changed in Akmola Region between 2005-2024. Materials and Methods. Twenty consecutive annual observations were assembled from Forms No. 7 and 35 of national cancer reporting system and from official estimates of the male resident population. For each calendar year, we derived population-based rates of newly diagnosed cases and prostate cancer deaths; incidence was additionally examined by age and stage at diagnosis. Log-linear Joinpoint models were fitted to the annual series, and temporal slopes were expressed as APC and, where applicable, AAPC, together with their 95% confidence intervals. Results. Registry returns contained 1,003 newly diagnosed cases and 413 deaths attributed to prostate cancer during the observation period. The standardized incidence series nearly doubled between the study endpoints, rising from 9.3 per 100,000 in 2005 to 19.2 in 2024; the model estimated an APC of 2.6% (p=0.002). Of all age strata, men aged 75-79 years had the highest mean annual incidence, at 189.5 per 100,000. For stages I-II, the incidence rate followed an upward trajectory (APC=3.3%; p=0.002), but these stages accounted for a progressively smaller share of all diagnoses, decreasing from 62.5% to 35.4%. A substantially steeper trajectory was observed for stage IV disease: its incidence rose from 1.4 to 10.6 per 100,000 (APC=9.8%; p<0.001), while its contribution to all registered cases expanded from 15.6% to 50.0%. Stage IV represented the largest diagnostic-stage category in 2022 and 2024. Although ASMR was lower at the end of follow-up than at baseline 5.6 versus 8.5 per 100,000 the fitted temporal slope did not differ statistically from zero (APC=−0.9%; p=0.616). Conclusions. Akmola Region experienced a clear rise in newly detected prostate cancer, with the steepest increase occurring in stage IV disease. Mortality showed no statistically reliable direction of change. The divergence between these indicators supports closer examination of regional diagnostic pathways, stage-recording practices, and subsequent population-based outcomes. Актуальность. Региональный анализ заболеваемости раком предстательной железы, стадийной структуры и смертности позволяет выявить эпидемиологические особенности, которые могут быть скрыты при оценке общенациональных показателей. Комплексные данные по Акмолинской области остаются ограниченными. Цель. Оценить возрастные особенности и многолетние тенденции заболеваемости, стадийной структуры при установлении диагноза и смертности от рака предстательной железы в Акмолинской области за 2005-2024 годы. Материалы и методы. Для 2005-2024 годов был сформирован региональный временной ряд, включавший 20 последовательных годовых наблюдений, полученных из сводных форм №7 и №35 национального канцер-регистра Республики Казахстан и официальной статистики мужского населения. В каждом календарном году зарегистрированное число новых случаев и смертей соотносили с соответствующей численностью мужского населения и выражали на 100 000 человек. Расчеты выполняли для всех возрастов без возрастной корректировки, для отдельных возрастных групп и с учетом различий в возрастной структуре населения. К годовым рядам применяли лог-линейные модели Joinpoint: направление и скорость изменения внутри каждого сегмента характеризовали посредством APC, а обобщенную динамику интервала с несколькими сегментами – посредством AAPC. Для обеих оценок приводили 95% доверительные интервалы. Результаты. Зарегистрировано 1 003 случая рака предстательной железы и 413 смертей от данного заболевания. Стандартизованный показатель заболеваемости увеличился с 9,3 на 100 000 мужчин в 2005 году до 19,2 в 2024 году (APC=2,6%; 95% ДИ: 1,0-4,7; p=0,002). Максимальный среднегодовой повозрастной показатель заболеваемости отмечен среди мужчин 75-79 лет – 189,5 на 100 000. Несмотря на увеличение заболеваемости опухолями I-II стадии (APC=3,3%; p=0,002), их доля снизилась с 62,5% до 35,4%. Заболеваемость опухолями IV стадии увеличилась с 1,4 до 10,6 на 100 000 мужчин (APC=9,8%; p<0,001), а их доля возросла с 15,6% до 50,0% и была наибольшей в 2022 и...

  • Open Access

    Тренды заболеваемости раком предстательной железы в Казахстане: Результаты компонентного анализа

    by Н.с. Игісін, Н.е. Ермек, И.ю. Шишкин, Ж.б. Тельманова, Г.с. Игисинова, Д.к. Туребаев, Р.с. Молдагали, С.с. Дьяков, А.е. Нарбаев, Д.м. Байбосынов, et al.

    The aim of this study is to assess the dynamics of prostate cancer incidence in Kazakhstan during the period 2005–2019 using component analysis methods. A retrospective epidemiological study was conducted based on data from the National Cancer Registry of Kazakhstan. Statistical methods included the calculation of age-standardized incidence rates, analysis of average annual growth rates, and component analysis of factors contributing to the increase in incidence. A total of 14,740 new prostate cancer cases were registered during the study period. The agestandardized incidence rate was 17.0 per 100.000 male population, showing an upward trend (T=+5.6%). The main factors contributing to the increase in incidence were changes in the age structure of the population (+10.9%), growthin the male population (+23.1%), and an increased risk of developing prostate cancer (+57.0%). The rising incidence of prostate cancer in Kazakhstan aligns with global trends and may be attributed to improved diagnostics, population aging, and changing risk factors. The findings can inform the development of prevention strategies, optimization of screening programs, and improvement of oncological care in the country.

  • Open Access

    State governance of social determinants of health in Kazakhstan: instruments, mechanisms, and strategic policy optimization

    by N. Y. Yermek, A. A. Tynyshbayeva, N. S. Igissin, Н. Е. Ермек

    Effective public governance of social determinants of health (SDH) is a fundamental factor in ensuring public well-being and the sustainable development of healthcare systems. This study examines key instruments and mechanisms for regulating SDH in the Republic of Kazakhstan, analyzing their impact on morbidity rates, life expectancy, and socio-economic inequalities. Special attention is given to the issue of healthcare workforce shortages, which significantly limit access to medical services and exacerbate regional disparities in population health. Strategic measures for reforming medical workforce training, distribution, and motivation are proposed, including targeted educational programs, mandatory graduate placements, and financial incentives to attract professionals to underserved regions. The research is based on an interdisciplinary approach, incorporating statistical analysis, a review of legal frameworks, and an examination of international and national experiences in public health. The study also identifies potential risks associated with the implementation of proposed measures, such as budgetary constraints and infrastructural barriers to healthcare digitalization. Furthermore, the study explores the influence of education, economic stability, working conditions, housing, nutrition, and healthcare accessibility on population health in Kazakhstan. The paper highlights best international practices and their potential adaptation to the Kazakhstani context. Policy recommendations focus on minimizing social inequalities, advancing digital healthcare technologies, expanding telemedicine, and reallocating budgetary resources toward disease prevention and early detection. The study concludes by emphasizing the necessity of a systemic and cross-sectoral approach to strengthen healthcare sustainability and improve population health outcomes in the long term.

  • Open Access

    Оценка заболеваемости раком предстательной железы в мегаполисах Казахстана

    by Cademy Of Public Administration Under The President Of The Republic Of Kazakhstan, Nariman Syzdykov, Serik Ayaganov, Kokshetau University named after Sh. Ualikhanov, Zhansaya Telmanova, Central Asian Institute for Medical Research, Ivan Shishkin, Dulat Turebaev, Astana Medical University, Akzhunis Jexenova, et al.

    Зерттеудің мақсаты: Қазақстанның екі ірі мегаполисінде – Алматы және Астана қалаларында қуықасты безінің қатерлі ісігімен аурушаңдықтың ерекшеліктерін зерделеу.Әдістері. Зерттеу материалы Қазақстан Республикасы Денсаулық сақтау министрлігінің 2005-2019 жылдардағы қуықасты безінің қатерлі ісігіне (ICD 10 – C61) қатысты №7 жылдық нысаны болды. Негізгі әдіс ретінде медициналық-биологиялықстатистиканың дескриптивті және аналитикалық әдістерін қолдана отырып, ретроспективті зерттеу қолданылды.Нәтижесі. 2005-2019 жылдары Қазақстанда 14 740 жаңа қуықасты безінің қатерлі ісігі жағдайы тіркелді, оның ішінде 2296 (15,6%) және 625 (4,2%) науқас Алматы және Астана қалаларына тиесілі болды. Алматы қаласында науқастардың орташажасы 70,7±0,4 жасты және Астана қаласында 69,2±0,3 жасты құрады. Зерттелген мегаполистерде қуықасты безінің қатерлі ісігімен сырқаттанушылықтың стандартталған көрсеткіші: Алматы қаласында – 28,1±2,50/0000 (95% СА=23,3-32,9) (T=+5,1%) және Астана қаласында – 24,2±2,00/0000 (95% СА=20,3-28,2) (T=+2,1%). Айырмашылық статистикалық тұрғыдан маңызды болмады (t=1,22, р=0,223). Зерттелген мегаполистердегі аурушаңдықтың жас көрсеткіштерін талдау 70 және одан жоғары жас тобындағыөсуін көрсетті.Қорытынды. Біздің зерттеуіміздің нәтижелері қуықасты безінің қатерлі ісігімен күресте пәнаралық тәсілдерді одан әрі зерттеу және дамыту қажеттілігін көрсетеді. Бұл аурудың алдын алу және ерте анықтау тиімділігін арттыруға, сондай-ақ емдеу нәтижелері мен науқастардың өмір сүру сапасын жақсартуға көмектеседі